DED Magnified: A Real-World Case Library – Case 2

Overview

Activity Description and Purpose

With a large treatment armamentarium available for dry eye disease (DED), it can be challenging to select the right treatment(s) for the right patient. In this second case of the DED Magnified: A Real-World Case Library series, Dr. Marc R. Bloomenstein identifies the tale-tell signs and symptoms of a case of evaporative DED and the optimization of treatment for the patient.

Target Audience

This educational activity is intended for ophthalmologists and optometrists.

Learning Objectives

After completing this activity, participants will be better able to:

• Review causative factors of dry eye disease
• Design evidence-based treatment plans for persons with dry eye disease

Registration Instructions

Clicking Register/Take course indicates that you have reviewed the CME/CE information for this activity.

Faculty Credentials

Faculty

Marc R. Bloomenstein, OD, FAAO Director of Optometric Services Schwartz Laser Eye Center Scottsdale, Arizona

Disclosure Policy

MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.

Faculty

Marc R. Bloomenstein, OD, is an advisory board member of AbbVie Inc, Alcon, Astellas Pharma Inc, Bausch & Lomb Incorporated, Bruder Healthcare, Harrow, Inc, Johnson & Johnson Vision Care, Inc, Novartis Pharmaceuticals Corporation, OCuSOFT Inc, Oyster Point Pharma, Inc, Reichert, Inc, Sight Sciences, STAAR Surgical, Sun Pharmaceutical Industries, Inc, Syndexis, Tarsus Pharmaceuticals, Inc, Thea Pharma Inc, and Topcon Medical Systems, Inc; and is on the speakers bureau for AbbVie Inc, Bausch & Lomb Incorporated, Dompé US, Inc, Oyster Point Pharma, Inc, Sight Sciences, Sun Pharmaceutical Industries, Inc, and Tarsus Pharmaceuticals, Inc.

Peer Reviewer

This activity was peer reviewed. The peer reviewer has no relevant financial relationships.

Planners, Managers, and Writers

MedEdicus planners, managers, and writers have no relevant commercial relationships to disclose.

Accreditation